查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1338907

出血性疾病市场、份额、规模、趋势、行业分析报告：按类型；按药物类别；按地区；按细分市场预测，2023-2032 年

Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球出血性疾病市场规模预计将达到 274.9 亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

最常见的血友病类型是血友病 A，当凝血因子 8 不足时就会发生这种疾病。 根据美国疾病管制与预防中心 (CDC) 的数据，美国每 10 万人中就有 10 人患有 A 型血友病。 凝血因子 9 缺乏会导致 B 型血友病。 根据疾病预防控制中心 (CDC) 的数据，B 型血友病影响着约十分之三的美国人。 这将推动未来几年出血性疾病市场的成长和需求。

A 型血友病患病率的增加、对该疾病的认识和筛检的提高、新疗法的进步以及该疾病患者预期寿命的延长都在推动出血性疾病市场的增长。Masu。 据 Statista 称，2021 年，A 型血友病将影响全球 185,318 人，另有 17,951 人受到各种血小板疾病的影响。 随着越来越多的患者被诊断出患有 A 型和 B 型血友病，对凝血因子替代疗法的需求不断增加，推动了市场的成长。

诸如血友病和冯维勒布兰德病等出血性疾病的特征是血液中凝血因子的缺乏或功能障碍。 患有出血性疾病的患者需要定期输注凝血因子替代疗法以预防或控制出血事件。 这些凝血因子主要来自捐赠的血液或血浆。 为了产生这些凝血因子，必须有捐赠者血液和血浆。

出血性疾病的盛行率不断增加，增加了对捐血和凝血因子替代治疗的需求。 根据世界卫生组织（WHO）统计，2008年至2018年，119个国家的自愿无偿捐血增加了1,070万人次。 这可能为出血性疾病市场的成长提供广泛的机会。

B型肝炎每年导致 60 万至 120 万人死亡，15% 至 40% 的感染患者会发展为致命的肝病（肝硬化、肝衰竭、肝细胞癌）。 肝硬化或肝细胞癌患者发生出血性疾病的风险增加，因为肝臟产生的凝血因子减少。 因此，这些患者对凝血因子替代疗法的需求量很大，推动了市场成长。

出血性疾病市场报告重点

由于甲型血友病患病率不断增加以及对新疗法的需求不断增加，预计甲型血友病将会成长。

由于预防需求的增加和製造技术的进步，重组凝血因子浓缩物实现了高成长率。

由于出血性疾病的盛行率不断增加以及研发投资的增加，预计亚太地区将出现强劲的成长率。

目录

第1章简介

第 2 章执行摘要

第3章研究方法

第 4 章全球出血性疾病市场洞察

  • 出血性疾病市场 - 产业概况
  • 出血性疾病的市场动态
    • 推动者和机会
      • 血友病患病率不断上升
      • 新兴国家对出血性疾病的认识不断提高
    • 抑制因素和挑战
      • 出血性疾病的治疗费用很高
  • 杵分析
  • 出血性疾病的产业趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第5章全球出血性疾病市场，依类型

  • 主要发现
  • 简介
  • 甲型血友病
  • B型血友病
  • 血管性血友病

第 6 章全球出血性疾病市场（依药物类别）

  • 主要发现
  • 简介
  • 血浆衍生凝血因子浓缩物
  • 重组凝血因子
  • 去氨加压素
  • 抗纤溶药物
  • 纤维蛋白密封剂

第 7 章全球出血性疾病市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年各地区出血性疾病市场评估
  • 出血性疾病市场 - 北美
    • 北美：出血性疾病市场，依药物类别，2019-2032 年
    • 北美：2019-2032 年出血性疾病市场（依类型）
    • 出血性疾病市场 - 美国
    • 出血性疾病市场 - 加拿大
  • 出血性疾病市场 - 欧洲
    • 欧洲：出血性疾病市场，依药物类别，2019-2032 年
    • 欧洲：出血性疾病市场（按类型），2019-2032 年
    • 出血性疾病市场 - 英国
    • 出血性疾病市场 - 法国
    • 出血性疾病市场 - 德国
    • 出血性疾病市场 - 义大利
    • 出血性疾病市场 - 西班牙
    • 出血性疾病市场 - 荷兰
    • 出血性疾病市场 - 俄罗斯
  • 出血性疾病市场 - 亚太地区
    • 亚太地区：出血性疾病市场（依药物类别），2019-2032 年
    • 亚太地区：2019-2032 年出血性疾病市场（按类型）
    • 出血性疾病市场 - 中国
    • 出血性疾病市场 - 印度
    • 出血性疾病市场 - 马来西亚
    • 出血性疾病市场 - 日本
    • 出血性疾病市场 - 印度尼西亚
    • 出血性疾病市场－韩国
  • 出血性疾病市场 - 中东和非洲
    • 中东和非洲：出血性疾病市场（按药物类别），2019-2032 年
    • 中东和非洲：2019-2032 年出血性疾病市场（按类型）
    • 出血性疾病市场 - 沙乌地阿拉伯
    • 出血性疾病市场 - 阿拉伯联合大公国
    • 出血性疾病市场 - 以色列
    • 出血性疾病市场 - 南非
  • 出血性疾病市场 - 拉丁美洲
    • 拉丁美洲：出血性疾病市场（依药物类别），2019-2032 年
    • 拉丁美洲：2019-2032 年出血性疾病市场（按类型）
    • 出血性疾病市场 - 墨西哥
    • 出血性疾病市场 - 巴西
    • 出血性疾病市场 - 阿根廷

第8章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第9章公司简介

  • Novo Nordisk
  • Bayer
  • Baxter
  • Alnylam Pharmaceuticals
  • Xenetic Biosciences
  • Bristol-Myers
  • Sanofi
  • Amgen
  • Janssen
  • Bioverativ Inc
Product Code: PM3351

The global bleeding disorders market size is expected to reach USD 27.49 billion by 2032, according to a new study by Polaris Market Research. The report "Bleeding Disorders Market Share, Size, Trends, Industry Analysis Report, By Type (Hemophilia A, Hemophilia B, Von Willebrand Diseases); By Drug Class; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The most prevalent kind of hemophilia is hemophilia A. It occurs when there is insufficient clotting factor 8. According to the Centres for Disease Control and Prevention (CDC), hemophilia A affects roughly 10 in every 100,000 persons in the United States. When clotting factor 9 levels are insufficient, hemophilia B develops. According to the CDC, hemophilia B affects roughly 3 in 100,000 Americans. This is driving the growth and demand for the bleeding disorders market in coming years.

The increasing prevalence of hemophilia A, greater awareness and screening for the disease, advances in new therapies, and the longer life expectancy of patients with the disease are all contributing factors to the growth of the bleeding disorders market. According to Statista, Hemophilia A affected 185,318 persons globally in 2021, while another 17,951 people had various platelet diseases. As more patients are diagnosed with hemophilia A and B, the demand for clotting factor replacement therapy increases, which fuels the growth of the market.

Bleeding disorders, such as hemophilia and von Willebrand disease, are characterized by a deficiency or dysfunction of clotting factors in the blood. Patients with bleeding disorders require regular infusions of clotting factor replacement therapy to prevent or control bleeding episodes. These clotting factors are primarily derived from donated blood and plasma. In order to produce these clotting factors, donor blood and plasma must be available.

Due to the rising prevalence of bleeding diseases, there is an increase in need for blood donations as well as clotting factor replacement therapy. According to the World Health Organization, 119 nations have recorded an increase in voluntary unpaid blood donations of 10.7 million from 2008 to 2018. This will create a wide range of opportunities for the growth of the bleeding disorders market.

HBV causes 600,000 to 1.2 million fatalities annually, with 15-40% of infected patients developing fatal liver conditions (cirrhosis, liver failure, and hepatocellular carcinoma). Patients with liver cirrhosis and HCC are at an increased risk of developing bleeding disorders due to the decreased production of clotting factors by the liver. As a result, the demand for clotting factor replacement therapy is high among these patients, which fuels the growth of the market.

Bleeding Disorders Market Report Highlights

Hemophilia A Type is anticipated to grow due to the increasing prevalence of hemophilia A and rising demand for novel therapies.

Recombinant Coagulation Factor Concentrates segment accounted for the higher growth rate owing to the growing demand for prophylaxis and advancements in manufacturing technology.

Asia Pacific is expected to grow at a significant growth rate owing to the increasing prevalence of bleeding disorders and investments in research & development.

The global players include: Novo Nordisk, Bayer, Baxter International, Alnylam Pharmaceuticals, Pfizer, Xenetic Biosciences, Bristol, Sanofi, Amgen, Janssen, and Bioverativ Inc.

Polaris Market Research has segmented the bleeding disorders market report based on type, drug class and region:

Bleeding Disorders, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Diseases

Bleeding Disorders, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Plasma Derived Coagulation Factor Concentrates
  • Recombinant Derived Coagulation Factor
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants

Bleeding Disorders, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Bleeding Disorders Market Insights

  • 4.1. Bleeding Disorders Market - Industry Snapshot
  • 4.2. Bleeding Disorders Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in prevalence of hemophilia
      • 4.2.1.2. Rise in awareness about bleeding disorders in developing countries
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of bleeding disorders treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Bleeding Disorders Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Bleeding Disorders Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Bleeding Disorders, by Type, 2019-2032 (USD Billion)
  • 5.3. Hemophilia A
    • 5.3.1. Global Bleeding Disorders Market, by Hemophilia A, by Region, 2019-2032 (USD Billion)
  • 5.4. Hemophilia B
    • 5.4.1. Global Bleeding Disorders Market, by Hemophilia B, by Region, 2019-2032 (USD Billion)
  • 5.5. Von Willebrand Diseases
    • 5.5.1. Global Bleeding Disorders Market, by Von Willebrand Diseases, by Region, 2019-2032 (USD Billion)

6. Global Bleeding Disorders Market, by Drug Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • 6.3. Plasma Derived Coagulation Factor Concentrates
    • 6.3.1. Global Bleeding Disorders Market, by Plasma Derived Coagulation Factor Concentrates, by Region, 2019-2032 (USD Billion)
  • 6.4. Recombinant Derived Coagulation Factor
    • 6.4.1. Global Bleeding Disorders Market, by Recombinant Derived Coagulation Factor, by Region, 2019-2032 (USD Billion)
  • 6.5. Desmopressin
    • 6.5.1. Global Bleeding Disorders Market, by Electric, by Region, 2019-2032 (USD Billion)
  • 6.6. Antifibrinolytics
    • 6.6.1. Global Bleeding Disorders Market, by Antifibrinolytics, by Region, 2019-2032 (USD Billion)
  • 6.7. Fibrin Sealants
    • 6.7.1. Global Bleeding Disorders Market, by Fibrin Sealants, by Region, 2019-2032 (USD Billion)

7. Global Bleeding Disorders Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Bleeding Disorders Market - North America
    • 7.3.1. North America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.3.2. North America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.3.3. Bleeding Disorders Market - U.S.
      • 7.3.3.1. U.S.: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.3.4. Bleeding Disorders Market - Canada
      • 7.3.4.1. Canada: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.4. Bleeding Disorders Market - Europe
    • 7.4.1. Europe: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.3. Bleeding Disorders Market - UK
      • 7.4.3.1. UK: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.4. Bleeding Disorders Market - France
      • 7.4.4.1. France: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.5. Bleeding Disorders Market - Germany
      • 7.4.5.1. Germany: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.6. Bleeding Disorders Market - Italy
      • 7.4.6.1. Italy: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.7. Bleeding Disorders Market - Spain
      • 7.4.7.1. Spain: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.8. Bleeding Disorders Market - Netherlands
      • 7.4.8.1. Netherlands: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.4.9. Bleeding Disorders Market - Russia
      • 7.4.9.1. Russia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.5. Bleeding Disorders Market - Asia Pacific
    • 7.5.1. Asia Pacific: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.3. Bleeding Disorders Market - China
      • 7.5.3.1. China: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.4. Bleeding Disorders Market - India
      • 7.5.4.1. India: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.5. Bleeding Disorders Market - Malaysia
      • 7.5.5.1. Malaysia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.6. Bleeding Disorders Market - Japan
      • 7.5.6.1. Japan: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.7. Bleeding Disorders Market - Indonesia
      • 7.5.7.1. Indonesia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.5.8. Bleeding Disorders Market - South Korea
      • 7.5.8.1. South Korea: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.6. Bleeding Disorders Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.3. Bleeding Disorders Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.4. Bleeding Disorders Market - UAE
      • 7.6.4.1. UAE: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.5. Bleeding Disorders Market - Israel
      • 7.6.5.1. Israel: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.6.6. Bleeding Disorders Market - South Africa
      • 7.6.6.1. South Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • 7.7. Bleeding Disorders Market - Latin America
    • 7.7.1. Latin America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.3. Bleeding Disorders Market - Mexico
      • 7.7.3.1. Mexico: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.4. Bleeding Disorders Market - Brazil
      • 7.7.4.1. Brazil: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
    • 7.7.5. Bleeding Disorders Market - Argentina
      • 7.7.5.1. Argentina: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Novo Nordisk
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Baxter
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Alnylam Pharmaceuticals
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Xenetic Biosciences
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Bristol-Myers
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Sanofi
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Amgen
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Janssen
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Bioverativ Inc
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development

List of Tables

  • Table 1 Global Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 5 North America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 7 U.S.: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 Canada: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 11 Europe: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 12 UK: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 13 UK: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 14 France: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 France: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 17 Germany: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 19 Italy: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 Spain: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 25 Russia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 28 China: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 29 China: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 30 India: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 31 India: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 35 Japan: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 South Korea: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 UAE: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 47 Israel: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 49 South Africa: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Latin America: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 53 Mexico: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 55 Brazil: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Bleeding Disorders Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 Argentina: Bleeding Disorders Market, by Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Bleeding Disorders Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Drug Class
  • Figure 7 Global Bleeding Disorders Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Type
  • Figure 9 Global Bleeding Disorders Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10 Bleeding Disorders Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Bleeding Disorders Market